Immunotherapy in combination with PARP inhibition in advanced cervical cancer patients functionally competent or deficient for the Fanconi anemia repair pathway.

John Paul Diaz; Wenrui Duan; Eric Schroeder; Zuanel Diaz; Nicholas Lambrou; Troy Antony Gatcliffe; Thomas Morrissey; Miguel Angel Villalona-Calero

doi:10.1200/JCO.2021.39.15_SUPPL.TPS5597

Immunotherapy in combination with PARP inhibition in advanced cervical cancer patients functionally competent or deficient for the Fanconi anemia repair pathway.

John Paul Diaz, Wenrui Duan, Eric Schroeder, Zuanel Diaz, Nicholas Lambrou, Troy Antony Gatcliffe, Thomas Morrissey, Miguel Angel Villalona-Calero

Miami Cancer Institute

Research output: Contribution to journal › Article › peer-review

Original language	American English
Journal	Journal of Clinical Oncology
Volume	39
DOIs	https://doi.org/10.1200/JCO.2021.39.15_SUPPL.TPS5597
State	Published - May 28 2021

Disciplines

Medicine and Health Sciences
Oncology

Access to Document

10.1200/JCO.2021.39.15_SUPPL.TPS5597License: Unspecified

Cite this

Diaz, J. P., Duan, W., Schroeder, E., Diaz, Z., Lambrou, N., Gatcliffe, T. A., Morrissey, T., & Villalona-Calero, M. A. (2021). Immunotherapy in combination with PARP inhibition in advanced cervical cancer patients functionally competent or deficient for the Fanconi anemia repair pathway. Journal of Clinical Oncology, 39. https://doi.org/10.1200/JCO.2021.39.15_SUPPL.TPS5597

@article{56fbcb5638b441628ed1057e75ce6d24,

title = "Immunotherapy in combination with PARP inhibition in advanced cervical cancer patients functionally competent or deficient for the Fanconi anemia repair pathway.",

author = "Diaz, {John Paul} and Wenrui Duan and Eric Schroeder and Zuanel Diaz and Nicholas Lambrou and Gatcliffe, {Troy Antony} and Thomas Morrissey and Villalona-Calero, {Miguel Angel}",

note = "TPS5597 Background: Immunotherapy has improved outcomes for patients with recurrent or metastatic cervical cancer whose tumors express PD-L1. Pembrolizumab (PEM), a monoclonal antibody that binds to programmed cell death 1 (PD 1) receptor, inhibits interaction with programmed cell death ligand 1 (PD-L1) and programmed cell death ligand 2 (PD-L2).",

year = "2021",

month = may,

day = "28",

doi = "10.1200/JCO.2021.39.15_SUPPL.TPS5597",

language = "American English",

volume = "39",

journal = "Journal of Clinical Oncology",

}

TY - JOUR

T1 - Immunotherapy in combination with PARP inhibition in advanced cervical cancer patients functionally competent or deficient for the Fanconi anemia repair pathway.

AU - Diaz, John Paul

AU - Duan, Wenrui

AU - Schroeder, Eric

AU - Diaz, Zuanel

AU - Lambrou, Nicholas

AU - Gatcliffe, Troy Antony

AU - Morrissey, Thomas

AU - Villalona-Calero, Miguel Angel

N1 - TPS5597 Background: Immunotherapy has improved outcomes for patients with recurrent or metastatic cervical cancer whose tumors express PD-L1. Pembrolizumab (PEM), a monoclonal antibody that binds to programmed cell death 1 (PD 1) receptor, inhibits interaction with programmed cell death ligand 1 (PD-L1) and programmed cell death ligand 2 (PD-L2).

PY - 2021/5/28

Y1 - 2021/5/28

UR - https://ascopubs.org/doi/abs/10.1200/JCO.2021.39.15_suppl.TPS5597

U2 - 10.1200/JCO.2021.39.15_SUPPL.TPS5597

DO - 10.1200/JCO.2021.39.15_SUPPL.TPS5597

M3 - Article

VL - 39

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

ER -

Immunotherapy in combination with PARP inhibition in advanced cervical cancer patients functionally competent or deficient for the Fanconi anemia repair pathway.

Disciplines

Access to Document

Other files and links

Cite this